Milestone Pharmaceuticals MIST 深 沪
等待开盘 10-01 09:30:00 美东时间
0.8657
+0.046
+5.57%
华盛通- 最 高0.8975
- 今 开0.838
- 成交量 126.88万股
- 最 低 0.82
- 昨 收 0.82
- 总市值 10.78万
- 52周最高 3.06
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 0.7521
- 委 比 -31.62%
- 总股本 0.00亿
- 历史最高 27.95
- 量 比 0.98
- 振 幅 9.45%
- 历史最低 0.6254
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Montreal Heart Institute has joined the ReVeRA-301 Phase 3 trial evaluating etripamil nasal spray for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, which aims to enroll 150 patients globally, is assessing the same 70 mg repeat-dose regimen approved for paroxysmal supraventricular tachycardia (PSVT). The primary endpoint is reducing ventricular rate within 30 minutes, with secondary endpoints focusing on symptom i...
09-24 12:00
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.
09-03 23:54
云顶新耀：星必妥新药上市申请获NMPA批准，用于治疗成人PSVT急性症状发作
9月3日，云顶新耀有限公司宣布，中国国家药品监督管理局（NMPA）已批准星必妥（艾曲帕米鼻喷雾剂）的新药上市许可申请，用于治疗成人阵发性室上性心动过速（PSV...
09-03 21:19
Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ dail...
08-27 20:01
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $3.
08-20 18:32
Milestone Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
Milestone Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-12 20:41
Milestone Pharmaceuticals Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $559.000K Miss $816.667K Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 10.53 percent. This is a 5 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $559.0...
08-12 19:02
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will report second-quarter 2026 financial results and provide a business update on Wednesday, August 12, before the market open. A conference call and webcast for investors will follow at 8:30am ET. Registration and dial-in details are available on the company's website. A replay of the webcast will be accessible post-event. Milestone is a biopharmaceutical company focused on innovative cardiovascular...
08-04 20:01
